JP2024506647A5 - - Google Patents

Info

Publication number
JP2024506647A5
JP2024506647A5 JP2023548583A JP2023548583A JP2024506647A5 JP 2024506647 A5 JP2024506647 A5 JP 2024506647A5 JP 2023548583 A JP2023548583 A JP 2023548583A JP 2023548583 A JP2023548583 A JP 2023548583A JP 2024506647 A5 JP2024506647 A5 JP 2024506647A5
Authority
JP
Japan
Prior art keywords
domain
transmembrane domain
seq
ccr4
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548583A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506647A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/015981 external-priority patent/WO2022173950A1/en
Publication of JP2024506647A publication Critical patent/JP2024506647A/ja
Publication of JP2024506647A5 publication Critical patent/JP2024506647A5/ja
Pending legal-status Critical Current

Links

JP2023548583A 2021-02-11 2022-02-10 Ccr4ターゲティングキメラ抗原受容体細胞療法 Pending JP2024506647A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163148489P 2021-02-11 2021-02-11
US63/148,489 2021-02-11
PCT/US2022/015981 WO2022173950A1 (en) 2021-02-11 2022-02-10 Ccr4-targeting chimeric antigen receptor cell therapy

Publications (2)

Publication Number Publication Date
JP2024506647A JP2024506647A (ja) 2024-02-14
JP2024506647A5 true JP2024506647A5 (cg-RX-API-DMAC7.html) 2025-02-19

Family

ID=82837290

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548583A Pending JP2024506647A (ja) 2021-02-11 2022-02-10 Ccr4ターゲティングキメラ抗原受容体細胞療法

Country Status (8)

Country Link
US (1) US20240122981A1 (cg-RX-API-DMAC7.html)
EP (1) EP4291207A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024506647A (cg-RX-API-DMAC7.html)
KR (1) KR20230171919A (cg-RX-API-DMAC7.html)
CN (1) CN117500838A (cg-RX-API-DMAC7.html)
AU (1) AU2022220694A1 (cg-RX-API-DMAC7.html)
CA (1) CA3207861A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022173950A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7818147B1 (ja) * 2025-01-23 2026-02-20 国立研究開発法人国立がん研究センター エフェクターt細胞、およびそれを含む医薬組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007013627A1 (ja) * 2005-07-28 2007-02-01 Kyowa Hakko Kogyo Co., Ltd. Bリンパ腫およびホジキンリンパ腫の治療剤
EP2476438B1 (en) * 2009-09-10 2014-07-23 Kyowa Hakko Kirin Co., Ltd. Medicament including antibody composition specifically bound to human cc chemokine receptor 4 (ccr4)
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
RU2017125531A (ru) * 2014-12-19 2019-01-21 Дана-Фарбер Кэнсер Инститьют, Инк. Химерные антигенные рецепторы и способы их применения
US20190112380A1 (en) * 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
WO2018057585A1 (en) * 2016-09-21 2018-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
WO2018101448A1 (en) * 2016-11-30 2018-06-07 Kyowa Hakko Kirin Co., Ltd. Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody
AU2019404302A1 (en) * 2018-12-19 2021-08-05 The Trustees Of The University Of Pennsylvania Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias
AU2020232789B2 (en) * 2019-03-06 2026-04-09 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
EP3934666A1 (en) * 2019-03-08 2022-01-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
EP4549555A3 (en) * 2019-05-24 2025-07-30 City of Hope Ccr4 targeted chimeric antigen receptor modified t cells for treatment of ccr4 positive malignancies
BR112021023897A2 (pt) * 2019-05-30 2022-01-25 Shandong Boan Biotechnology Co Ltd Anticorpo ou receptor de antígeno quimérico que visa claudina18.2

Similar Documents

Publication Publication Date Title
AU2022200257B2 (en) Chimeric antigen receptors and methods of use thereof
JP2022548778A5 (cg-RX-API-DMAC7.html)
CA3032054A1 (en) Combination therapies of chimeric antigen receptors and pd-1 inhibitors
JP2016514462A5 (cg-RX-API-DMAC7.html)
JP2022512882A5 (cg-RX-API-DMAC7.html)
US20210128618A1 (en) Bcma-targeted car-t cell therapy of multiple myeloma
TWI915404B (zh) 用於治療egfr陽性癌症之組合物及方法
US20240000938A1 (en) Adoptive cell therapy for treatment of cancer associated with loss of heterozygosity
KR20210049806A (ko) Nef-함유 T 세포 및 이의 생산 방법
AU2021338819A1 (en) Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof
CN112204135B (zh) 一种表达cd3抗体受体复合物的免疫细胞及其用途
JP2021520780A (ja) Nkg2dキメラ抗原受容体
CA3110858A1 (en) Methods and compositions comprising b7h3 chimeric antigen receptors
IL304857A (en) Preparations and methods for treating HER2 POSITIVE cancer
CN114828862A (zh) 使用融合蛋白进行tcr重编程的组合物和方法
EP4598567A2 (en) Novel anti-mesothelin chimeric antigen receptors and modified immune cells
JP2022526720A5 (cg-RX-API-DMAC7.html)
IL303060A (en) Chimeric receptors and methods of their use
US20220370498A1 (en) Immune cells expressing receptor specific to class i mhc molecule and interfering rna for hla gene
US20220315931A1 (en) Immune cells expressing receptor specific to class i mhc molecule and interfering rna for beta2 microglobulin gene
CN120712289A (zh) 抗原结合结构域及其使用方法
RU2843842C1 (ru) Композиции и способы для лечения egfr-положительных форм рака
WO2023081767A1 (en) Methods for immunotherapy
WO2025006499A2 (en) Gpc3-targeted molecules and uses thereof
EP4649093A2 (en) Blockade of cd8 expression and chimeric antigen receptors for immunotherapy of t-cell and nk-cell malignancies